Medline Analyst Price Targets - Benzinga

Medline Inc

MDLNNASDAQ

Trade with Public

Trade with Public

$37.26

3.179.3%

마지막 업데이트: Nov 4, 9:29 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Medline Analyst Price Targets

Wall Street analyst price targets and consensus rating for Medline (MDLN).

Price Target Range — 4 Quarters

Analyst Consensus — 23 Analysts

20Buy

3Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$47Upside to Avg. PT+25.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	Mizuho	Steven Valiquette	PT Cut	Outperform	$48→$45
Oct 9, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$45→$43
Sep 25, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$45→$43
Aug 27, 2026	BTIG	David Larsen	Maintained	Buy	$55
Aug 12, 2026	JP Morgan	Lisa Gill	PT Cut	Overweight	$53→$46
Aug 11, 2026	Tigress Financial	Ivan Feinseth	PT Cut	Buy	$62→$55
Aug 11, 2026	Wells Fargo	Stephen Baxter	PT Cut	Equal-Weight	$45→$34
Aug 10, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$53→$45
Aug 6, 2026	RBC Capital	Ryan Halsted	PT Cut	Outperform	$53→$46
Aug 6, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$56→$47
Aug 6, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$48→$39
Aug 6, 2026	Stifel	Rick Wise	PT Cut	Buy	$50→$45
Jul 31, 2026	BTIG	David Larsen	Maintained	Buy	$55
Jun 3, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$57→$45
Jun 1, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$50→$45
May 14, 2026	BNP Paribas	Navann Ty	PT Cut	Neutral	$49→$40
May 13, 2026	Tigress Financial	Ivan Feinseth	PT Raise	Buy	$60→$62
May 7, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$60→$55
May 7, 2026	Bernstein	Lee Hambright	PT Cut	Outperform	$56→$54
May 7, 2026	BTIG	David Larsen	Maintained	Buy	$55

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Medline, Lowers Price Target to $43

Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Medline, Lowers Price Target to $43

UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Medline, Maintains $55 Price Target

BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46

JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34

Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.

Benzinga Newsdesk